Insider Trading Alert - HAFC, AMRI And USTR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 11, 2014, 103 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $337.00 to $15,638,127.00.

Highlighted Stocks Traded by Insiders:

Hanmi Financial (HAFC) - FREE Research Report

Lee Joon Hyung, who is Director at Hanmi Financial, sold 1,000 shares at $21.58 on Dec. 11, 2014. Following this transaction, the Director owned 277,697 shares meaning that the stake was reduced by 0.36% with the 1,000-share transaction.

The shares most recently traded at $21.28, down $0.30, or 1.41% since the insider transaction. Historical insider transactions for Hanmi Financial go as follows:

  • 4-Week # shares bought: 8,750
  • 4-Week # shares sold: 13,000
  • 12-Week # shares bought: 8,750
  • 12-Week # shares sold: 17,000
  • 24-Week # shares bought: 8,750
  • 24-Week # shares sold: 17,000

The average volume for Hanmi Financial has been 157,300 shares per day over the past 30 days. Hanmi Financial has a market cap of $697.4 million and is part of the financial sector and banking industry. Shares are down 3.43% year-to-date as of the close of trading on Wednesday.

Hanmi Financial Corporation operates as the holding company for Hanmi Bank that operates as a community bank in the United States. The stock currently has a dividend yield of 1.28%. The company has a P/E ratio of 15.2. Currently, there are 6 analysts who rate Hanmi Financial a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HAFC - FREE

TheStreet Quant Ratings rates Hanmi Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, increase in net income, growth in earnings per share and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Hanmi Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Albany Molecular Research (AMRI) - FREE Research Report

D Ambra Constance M, who is 10% Owner at Albany Molecular Research, sold 20,000 shares at $16.24 on Dec. 11, 2014. Following this transaction, the 10% Owner owned 2.5 million shares meaning that the stake was reduced by 0.78% with the 20,000-share transaction.

D Ambra Thomas E Phd, who is Chairman, Board of Directors at Albany Molecular Research, sold 20,000 shares at $16.24 on Dec. 11, 2014. Following this transaction, the Chairman, Board of Directors owned 2.7 million shares meaning that the stake was reduced by 0.74% with the 20,000-share transaction.

The shares most recently traded at $15.98, down $0.26, or 1.63% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 81,000
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 209,297

The average volume for Albany Molecular Research has been 486,700 shares per day over the past 30 days. Albany Molecular Research has a market cap of $543.6 million and is part of the health care sector and drugs industry. Shares are up 59.82% year-to-date as of the close of trading on Wednesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 138.9. Currently, there are 2 analysts who rate Albany Molecular Research a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

United Stationers (USTR) - FREE Research Report

Blanchard Eric A, who is Sr VP, Gen Counsel & Secretary at United Stationers, sold 1,941 shares at $42.99 on Dec. 11, 2014. Following this transaction, the Sr VP, Gen Counsel & Secretary owned 20,358 shares meaning that the stake was reduced by 8.7% with the 1,941-share transaction.

The shares most recently traded at $40.16, down $2.83, or 7.05% since the insider transaction. Historical insider transactions for United Stationers go as follows:

  • 4-Week # shares sold: 4,793
  • 12-Week # shares sold: 4,793
  • 24-Week # shares sold: 16,461

The average volume for United Stationers has been 171,600 shares per day over the past 30 days. United Stationers has a market cap of $1.7 billion and is part of the services sector and wholesale industry. Shares are down 10.76% year-to-date as of the close of trading on Wednesday.

United Stationers Inc. operates as a wholesale distributor of business products in the United States and internationally. The stock currently has a dividend yield of 1.3%. The company has a P/E ratio of 13.3. Currently, there are no analysts who rate United Stationers a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on USTR - FREE

TheStreet Quant Ratings rates United Stationers as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full United Stationers Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company